Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease

Journal of Medicinal Chemistry

Volumn 51, Issue 18, 2008, Pages 5471-5489

  Kodimuthali, Arumugam ^a   Lal Jabaris, S Sugin ^a   Pal, Manojit ^a  

^a Matrix Laboratories Limited   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPENTYL 3 ETHYL 4,5,6,7 TETRAHYDRO 6 (2 METHYLPHENYL) 7 OXO 1H PYRAZOLO[3,4 C]PYRIDINE; 1,7 NAPHTHYRIDINE DERIVATIVE; 2 TRIFLUOROMETHYL DERIVATIVE; 4 (3 CHLOROPHENYL) 1,7 DIETHYLPYRIDO[2,3 D]PYRIMIDIN 2(1H) ONE; 4,6 PYRIMIDINEDIAMINE DERIVATIVE; 5 PHENYLIMIDAZO[4,5 C][1,8]NAPHTHYRIDIN 4(5H) ONE; 8 BIARYLQUINOLINE DERIVATIVE; 8 METHOXYQUINOLINE 4 CARBOXYLIC ACID (3,5 DICHLOROPYRIDYL 4 YL)AMIDE; 9 AMINOTETRAHYDRODIAZEPINOINDOLE DERIVATIVE; 9 BENZYLADENINE DERIVATIVE; ANTIASTHMATIC AGENT; CILOMILAST; CYCLIC AMP; CYCLIC GMP; GW 3600; KF 18280; KF 19514; NAPHTHALENE DERIVATIVE; PHOSPHODIESTERASE; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; PYRAZOLE DERIVATIVE; PYRAZOLOPYRIDINE DERIVATIVE; ROFLUMILAST; ROLIPRAM; RS 14491; RS 17597; TOFIMILAST; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZARDAVERINE;

ASTHMA; BINDING AFFINITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE RELEASE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EOSINOPHIL; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; MORTALITY; NAUSEA; NONHUMAN; PHARMACOPHORE; RESPIRATORY SYSTEM; REVIEW; SIDE EFFECT; STOMACH ACID SECRETION; STRUCTURE ACTIVITY RELATION; VOMITING;

ASTHMA; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HUMANS; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 52449115420     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800582j     Document Type: Review

References (126)

1. (a) Rennard, S. I. Treatment of stable chronic obstructive pulmonary disease. Lancet 2004, 364, 791-802.
2. (b) Sutherland, E. R.; Cherniack, R. M. Current concepts: management of chronic obstructive pulmonary disease. N. Engl. J. Med 2004, 350, 2689-2697.
3. Potter, B. V. L. Transmembrane Signalling Second Messenger Analogues and Inositol Phosphates. In Comprehensive Medicinal Chemistry; Hansch, C., Sammes, P. G., Taylor, J. B., Eds.; Pergamon Press: Oxford, U.K., 1990; pp 102-128.
4. Manallack, D. T.; Hughes, R. A.; Thompson, P. E. The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J. Med. Chem. 2005, 48, 3449-3462.
5. Card, G. L.; England, B. P.; Suzuki, Y.; Fong, D.; Powell, B.; Lee, B.; Luu, C.; Tabrizizad, M.; Gillete, S.; Ibrahim, P. N.; Artis, D. R.; Bollag, G.; Milburn, M. V.; Kim, S.; Schlessinger, J.; Zang, K. Y. J. Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 2004, 12, 2233-2247.
6. (a) Houslay, M. D.; Sullivan, M.; Bolger, G. B. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv. Pharmacol. 1998, 44, 225-342.
7. (b) Spina, D. The potential of PDE4 inhibitors in asthma or COPD. Curr. Opin. Invest. Drugs 2000, 1, 204-213.
8. Richter, W.; Conti, M. Dimerization of the type 4 cAMP-specific phosphodiesterases is mediated by the upstream conserved regions (UCRs). J. Biol. Chem. 2002, 277, 40212-40221.
9. Hogg, J. C.; Chu, F.; Utokaparch, S.; Woods, R.; Elliott, W. M.; Buzatu, L.; Cherniack, R. M.; Rogers, R. M.; Sciurba, F. C.; Coxson, H. O.; Pare, P. D. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med 2004, 350, 2645-2653.
10. Bourne, H. R.; Lichtenstein, L. M.; Melmon, K. L.; Henny, C. S.; Weinstein, Y.; Shearer, G. M. Modulation of inflammation and immunity by cyclic AMP. Receptors for vasoactive hormones and mediators of inflammation regulate many leukocyte functions. Science 1974, 184, 19-28.
11. Lobban, M.; Shakur, Y.; Beattie, J.; Houslay, M. D. Identification of two splice variant forms of type-IV B cyclic AMP phosphodiesterase, DPD (rPDE-IV B1) and PDE-4 (rPDE-IV B2) in brain; selective localization in membrane and cytosolic comparments and differential expression in various brain regions. Biochem. J. 1994, 304, 399-406.
12. Byers, D.; Davis, R. L.; Kiger, J. A., Jr. Defect in cyclic AMP phosphodiesterase due to the dunce mutation of learning in Drosophila melanogaster. Nature 1981, 289, 79-81.
13. Qiu, Y. H.; Chen, C. N.; Malone, T.; Richter, L.; Beckendorf, S. K.; Davis, R. L. Characterization of the memory gene dunce of Drosophila melanogaster. J. Mol. Biol. 1991, 222, 553-565.
14. (a) Tilley, D. G.; Maurice, D. H. Vascular smooth muscle cell phenotype-dependent phosphodiesterase 4D short form expression: role of differential histone acetylation on cAMP-regulated function. Mol. Pharmacol. 2005, 68, 596-605.
15. (b) Reneland, R. H.; Mah, S.; Kammerer, S.; Hoyal, C. R.; Marnellos, G.; Wilson, S. G.; Sambrook, P. N.; Spector, T. D.; Nelson, M. R.; Braun, A. Association between a variation in the phosphodiesterase 4D gene and bone mineral density. BMC Med. Genet 2005, 6, 9 (doi:10.1186/1471-2350-6-9).
16. (a) Houslay, M. D.; Sullivan, M.; Bolger, G. B. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv. Pharmacol. 1998, 44, 225-342.
17. (b) Bolger, G.; Michaeli, T.; Martins, T.; Souness, J. E.; Rao, S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell. Signalling 1997, 9, 227-236.
18. (c) Muller, T.; Engel, P.; Fozard, J. R. Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. TIPS 1996, 17, 294-298.
19. (d) Engels, P.; Adbel' Al, S.; Hulley, P. Brain distribution of four rat homologues of the Drosophila dunce cAMP phosphodiesterase. J. Neurosci. Res. 1995, 41, 169-178.
20. (a) Hanton, G.; Sobry, C.; Daguès, N.; Provost, J.-P.; Le Net, J.-L.; Comby, P.; Chevalier, S. Characterisation of the vascular and inflammatory lesions induced by the PDE4 inhibitor CI-1044 in the dog. Toxicol. Lett. 2008, 179, 15-22.
21. (b) Daguès, N.; Pawlowski, V.; Sobry, C.; Hanton, G.; Borde, F.; Soler, S.; Freslon, J.-L.; Chevalier, S. Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker. Toxicol. Sci. 2007, 100, 238-247.
22. (c) Stachlewitz, R. F. Bringing biomarkers to the masses: an elegant approach to discover potential biomarkers of vascular injury. Toxicol. Sci. 2007, 100, 5-6.
23. (d) McCluskie, K.; Klein, U.; Linnevers, C.; Ji, Y.-h.; Yang, A.; Husfeld, C.; Thomas, G. R. Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo. J. Pharmacol. Exp. Ther. 2006, 319, 468-476.
24. (e) Verghese, M. W.; McComrenell, R. T.; Strickland, A. B.; Goodmg, R. C.; Stimpson, S. A.; Yamall, D. P.; Taylor, J. D.; Furdon, P. J. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J. Pharmacol. Exp. Ther. 1995, 272, 1313-1320.
25. (f) Renz, H.; Gong, J. H.; Schmidt, A.; Nain, M.; Gemsa, D. Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. J. Immunol. 1988, 141, 2388-2393.
26. Davis, C. W. Assessment of selective inhibition of rat cerebral cortical calcium-independent and calcium-dependent phosphodiesterases in crude extracts using deoxycyclic AMP and potassium ions. Biochem. Biophys. Acta 1984, 797, 354-362.
27. Schneider, H. H.; Schmiechen, R.; Brezinski, M.; Seidler, J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. J. Pharmacol. 1986, 127, 105-115.
28. 3H]rolipram. Brain Res. 1989, 503, 229-245.
29. Glaser, T.; Traber, J. TVX 2706, a new phosphodiesterase inhibitor with antiinflammatory action. Biochemical characterization. Agents Actions 1984, 15, 341-348.
30. Russo, L. L.; Lebel, L. A.; Koe, B. K. Effects of selected phosphodiesterase PDE inhibitors on calcium-independent PDE activity and rolipram binding sites of cerebral cortex. Soc. Neurosci. Abstr. 1987, 13, 903.
31. Whilhelm, R.; Loe, B.; Alvarez, R.; Devens, B.; Fong, A. Pyrido[2,3-d]pyridazinones as Potent and Selective Type IV Phosphodiesterase Inhibitors. Presented at the 8th RSC-SCI Medicinal Chemistry Symposium, Cambridge, U.K., September 10-13, 1995; P-32.
32. 3H]rolipram binding site: 3-norbornyloxy-4- methoxyphenylmethylene oxindoles. Bioorg. Med. Chem. Lett. 1995, 5, 1965-1968.
33. 3H]rolipram binding site. Bioorg. Med. Chem. Lett. 1995, 5, 1969-1972.
34. (a) Crespo, M. I.; Pages, L.; Vega, A.; Segarra, V.; Lopez, M.; Domenech, T.; Miralpeix, M.; Beleta, J.; Ryder, H.; Palacios, J. M. Design, synthesis, and biological activities of new thieno[3,2-d]pyrimidines as selective type 4 phosphodiesterase inhibitors. J. Med. Chem. 1998, 41, 4021-4035.
35. (b) Lowe, J. A., III; Archer, R. L.; Chapin, D. S.; Cheng, J. B.; Helweg, D.; Johnson, J. L.; Koe, B. K.; Lebel, L. A.; Moore, P. F.; Nielsen, J. A.; Russo, L. L.; Shirley, J. T. Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase. J. Med. Chem. 1991, 34, 624-628.
36. (c) Alvarez, R.;.; Wilhelm, R.; Shelton, E. R.; Daniels, D. V.; Yang, D.; Kelly, K.; Eglen, R. M. Potent and selective inhibition of cyclic AMP specific phosphodiesterase (PDE 4) by structural analogues of nitraquazone. Can. J. Physiol. Pharmacol. 1994, 72 (Suppl. 1), 510 Abst. P18.2.11.
37. Bourguignon, J.-J.; Desaubry, L.; Raboisson, P.; Wermuth, C.-G.; Lugnier, C. 9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors. J. Med. Chem. 1997, 40, 1768-1770.
38. Butt, E.; Beltman, J.; Becker, D. E.; Jensen, G. S.; Rybalkin, S. D.; Jastorff, B.; Beavo, J. A. Characterization of cyclic nucleotide phosphodiesterases with cyclic AMP analogs: topology of the catalytic sites and comparison with other cyclic AMP-binding proteins. Mol. Pharmacol. 1995, 47, 340-347.
39. Ashton, M. J.; Cook, D. C.; Fenton, G.; Karlsson, J.-A.; Palfreyman, M. N.; Raeburn, D.; Ratcliff, A. J.; Souness, J. E.; Thurairatnam, S.; Vicker, N. Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The synthesis and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues. J. Med. Chem. 1994, 37, 1696-1703.
40. Hatzelmann, A.; Schudt, C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 2001, 297, 267-279.
41. Stafford, J. A.; Veal, J. M.; Feldman, P. L.; Valvano, N. L.; Baer, P. G.; Brackeen, M. F.; Brawley, E. S.; Connolly, K. M.; Domanico, P. L.; Han, B.; Rose, D. A.; Rutkowske, R. D.; Sekut, L.; Stimpson, S. A.; Strickland, A, B.; Verghese, M. W. Introduction of a conformational switching element on a pyrrolidine ring. Synthesis and evaluation of (R*,R*)- (±)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1- pyrrolidinecarboxylate, a potent and selective inhibitor of cAMP-specific phosphodiesterase. J. Med. Chem. 1995, 38, 4972-4975.
42. (a) Francis, S. H.; Colbran, J. L.; McAllister-Lucas, L. M.; Corbin, J. D. Zinc interactions and conserved motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase. J. Biol. Chem. 1994, 269, 22477-22480.
43. (b) Kleinman, E. F.; Campbell, E.; Giordano, L. A.; Cohan, V. L.; Jenkinson, T. H.; Cheng, J. B.; Shirley, J. T.; Pettipher, E. R.; Salter, E. D.; Hibbs, T. A.; DiCapua, F. M.; Bordner, J. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNFα inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4. J. Med. Chem. 1998, 41, 266-270.
44. (a) Warrellow, G. J.; Alexander, R. P.; Boyd, E. C.; Eaton, M. A.; Head, J. C.; Higgs, G. A. Presented at the 8th RSC-XI Medicinal Chemistry Symposium, Cambridge, U.K., 1995.
45. (b) WarmBow, G. J. The Design and Synthesis of Novel Triarylethanes as Potent, Selective, orally Active PDE4 Inhibitors for Asthma Presented at Peptidomimetics & Small Molecule Design, Washington DC, March 6-8, 1996.
46. (a) Guay, D.; Hamel, P.; Blouin, M.; Brideau, C.; Chan, C. C.; Chauret, N.; Ducharme, Y.; Huang, Z.; Girard, M.; Jones, T. R.; Laliberte', F.; Li, C.; Masson, P.; McAuliffe, M.; Piechuta, H.; Silva, J.; Young, R. N.; Girard, Y. Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor. Bioorg. Med. Chem. Lett. 2002, 12, 1457-1461.
47. (b) Frenette, R.; Blouin, M.; Brideau, C.; Chauret, N.; Ducharme, Y.; Friesen, R. W.; Hamel, P.; Jones, T. R.; Laliberte, F.; Li, C.; Masson, P.; McAuliffe, M.; Girard, Y. Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters. Bioorg. Med. Chem. Lett. 2002, 12, 3009-3013.
48. (c) Cote, B.; Frenette, R.; Prescott, S.; Blouin, M.; Brideau, C.; Ducharme, Y.; Friesen, R. W.; Laliberte, F.; Masson, P.; Styhler, A.; Girard, Y. Substituted aminopyridines as potent and selective phosphodiesterase-4 inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 741-744.
49. (d) Hulme, C.; Poli, G. B.; Huang, F.-C.; Souness, J. E.; Djuric, S. W. Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles. Bioorg. Med. Chem. Lett. 1998, 8, 175-178.
50. Hulme, C.; Moriarty, K.; Miller, B.; Mathew, R.; Ramanjulu, M.; Cox, P.; Souness, J.; Page, K. M.; Uhl, J.; Travis, J.; Huang, F.-c.; Labaudiniere, R.; Djuric, S. W. The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I. Bioorg. Med. Chem. Lett. 1998, 8, 1867-1872.
51. Marfat, A. Substituted Indazole Derivatives and Their Use as Inhibitors Phosphodiesterase (PDE) Type IV and Production of Tumor Necrosis Factor (TNF) World Patent Application WO9742174-A1, November 13, 1997.
52. Stafford, J. A.; Feldman, P. L.; Marron, B. E.; Schoenen, F. J.; Valvano, N. L.; Unwalla, R. J.; Domanico, P. L.; Brawley, E. S.; Leesnitzer, M. A.; Rose, D. A.; Dougherty, R. W. Bioorg. Med. Chem. Lett. 1994, 4, 1855-1858.
53. (a) Amschler, H.; Flockerzi, D.; Gutterer, B.; Hatzelmann, A.; Schudt, C.; Beume, R.; Hafner, D.; Kley, H.-P.; Ulrich, W.-R.; Thibaut, U. Dihydrobenzofurans. World Patent Application WO 96/03399, February 8, 1996.
54. (b) Dyke, H. J.; Lowe, C.; Montana, J. G.; Kendall, H. J.; Sabin, V. J. Benzofuran Carboxamides and Their Therapeutic Use. World Patent Application WO 97/44337, November 27, 1997.
55. (a) Regan, J.; Bruno, J.; McGarry, D.; Poli, G.; Hanney, B.; Bower, S.; Travis, J.; Sweeney, D.; Miller, B.; Souness, J.; Djuric, S. 2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 2737-2742.
56. (b) McGarry, D. G.; Regan, J. R.; Volz, F. A.; Hulme, C.; Moriarty, K. J.; Djuric, S. W.; Souness, J. E.; Miller, B. E.; Travis, J. J.; Sweeney, D. M. Benzofuran based PDE4 inhibitors. Bioorg. Med. Chem. 1999, 7, 1131-1139.
57. (c) Buckley, G.; Cooper, N.; Dyke, H. J.; Galleway, F.; Gowers, L.; Gregory, J. C.; Hannah, D. R.; Haughan, A. F.; Hellewell, P. G.; Kendall, H. J.; Lowe, C.; Maxey, R.; Montana, J. G.; Naylor, R.; Picken, C. L.; Runcie, K. A.; Sabin, V.; Tuladhar, B. R.; Warneck, J. B. H. 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma. Bioorg. Med. Chem. Lett. 2000, 10, 2137-2140.
58. (d) Buckley, G. M.; Cooper, N.; Davenport, R. J.; Dyke, H. J.; Galleway, F. P.; Gowers, L.; Haughan, A. F.; Kendall, H. J.; Lowe, C.; Montana, J. G.; Oxford, J.; Peake, J. C.; Picken, C. L.; Richard, M. D.; Sabin, V.; Sharpe, A.; Warneck, J. B. H. 7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma. Bioorg. Med. Chem. Lett. 2002, 12, 509-512.
59. Montana, J. G.; Buckley, G. M.; Cooper, N.; Dyke, H. J.; Gowers, L.; Gregory, J. P.; Hellewell, P. G.; Kendall, H. J.; Lowe, C.; Maxey, R.; Miotla, J.; Naylor, R. J.; Runcie, K. A.; Tuladhar, B.; Warneck, J. B. H. Aryl sulfonamides as selective PDE4 inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 2635-2640.
60. (a) Bacher, E.; Boer, C.; Bray-French, K.; Demnitz, F. W. J.; Keller, T. H.; Mazzoni, L.; Müller, T.; Walker, C. N-Arylrolipram derivatives as potent and selective PDE4 inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 3229-3234.
61. (b) Amari, G.; Armani, E.; Ghidini, E. Derivatives of 1-Phenyl-2-pyridinyl Alkylene Alcohols as Phosphodiesterase Inhibitors. World Patent Application WO/2008/006509, January 17, 2008.
62. (a) Teixeira, M. M.; Gristwood, R. W.; Cooper, N.; Hellewell, P. G. Phosphodiesterase (PDE)4 inhibitors: antiinflammatory drugs of the future. TIPS 1997, 18, 164-171.
63. (b) Banner, K. H.; Page, C. P. Antiinflammatory effects of theophylline and selective phosphodiesterase inhibitors. Clin. Exp. Allergy 1996, 26 (Suppl. 2), 2-9.
64. Perasson, C. G.; Andersson, K. E.; Kjellin, G. Effects of enprofylline and theophylline may show the role of adenosine. Life Sci. 1986, 38, 1057-1072.
65. Montana, J. G.; Cooper, N.; Dyke, H. J.; Gowers, L.; Gregory, J. P.; Hellewell, P. G.; Miotla, J.; Morris, K.; Naylor, R.; Tuladhar, B.; Warneck, J. B. H. PDE4 inhibitors: new xanthine analogues. Bioorg. Med. Chem. Lett. 1998, 8, 2925-2930.
66. Muller, G. W.; Shire, M. G.; Wong, L. M.; Corral, L. G.; Patterson, R. T.; Chen, Y.; Stirling, D. I. Thalidomide analogs and PDE4 inhibition. Bioorg. Med. Chem. Lett. 1998, 8, 2669-2674.
67. Christensen, S. B.; Guider, A.; Forster, C. M.; Gleason, J. G.; Bender, P. E.; Karpinski, J. M.; DeWolf, W. E., Jr.; Barnette, M. S.; Underwood, D. C.; Griswold, D. E.; Cieslinski, L. B.; Burman, M.; Bochnowicz, S.; Osbom, R. R.; Manning, C. D.; Grous, M.; Hillegas, L. M.; Bartus, J. O.; Ryan, M. D.; Eggleston, D. S.; Haltiwanger, R. C.; Torphy, T. J. J. Med. Chem. 1998, 41, 821-835.
68. (a) Marivet, M. C.; Bourguignon, J.-J.; Lugnier, C.; Mann, A.; Stoclet, J.-C.; Wermuth, C.-G. Inhibition of cyclic adenosine-3′,5′-phosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. J. Med. Chem. 1989, 32, 1450-1457.
69. (b) Murdoch, R. D.; Cowley, H.; Upward, J.; Webber, D.; Wyld, P. The safety and tolerability of Ariflo (SB207499), a novel and selective phospodiesterease 4 inhibitor, in healthy male volunteers. Am. J. Respir. Crit. Care Med. 1998, 157, Poster L57.
70. Wilson, M.; Sullivan, M.; Brown, N.; Houslay, M. D. Purification, characterization and analysis of rolipram inhibition of a human type-IVA cyclic AMP-specific phosphodiesterase expressed in yeast. Biochem. J. 1994, 304, 407-415.
71. (a) Giembycz, M. A. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin. Invest. Drugs 2001, 10, 1361-1379.
72. (b) Dyke, H. J.; Montana, J. G. The therapeutic potential of PDE4 inhibitors. Expert Opin. Invest. Drugs 1999, 8, 1301-1325.
73. Ochiai, H.; Ohtani, T.; Ishida, A.; Kishikawa, K.; Obata, T.; Nakai, H.; Toda, M. Orally active PDE4 inhibitors with therapeutic potential. Bioorg. Med. Chem. Lett. 2004, 14, 1323-1327.
74. Abraham, T.; Gopalan, B.; Atmaram, G. L.; Raghunath, M. J.; Rao, L. V. S. P.; Dawoodbhai, L. A.; Usha, K.; Ruchi, V. Condensed Heterocyclic Compounds as PDE-IV Inhibitors for the Treatment of Inflammatory and Allergic Disorder. World Patent Application WO 2004/016596 A1, February 26, 2004.
75. Christensen, S. B., IV; Bender, P. E.; Forster, C. J. Compounds Useful for Treating Allergic or Inflammatory Diseases. U.S. Patent Application US5811455, September 22, 1998.
76. Gopalan, B.; Atmaram, G. L.; Khairatkar, J. N. New Tricyclic Compounds Useful for the Treatment of Inflammatory and Allergic Disorders: Process for Their Preparation and Pharmaceutical Composition Containing Them. World Patent Application WO 2006/011024, February 2, 2006.
77. Gopalan, B.; Dhamjewar, R.; Havale, S.; Hosamane, S. S. K. Dibenzofuran Derivatives as Inhibitors of PDE-4 and PDE-10. World Patent Application WO 2008/032171 A1, March 20, 2008.
78. Cavalla, D.; Chasin, M.; Hofer, P.; Gehrig, A.; Wintergerst, P. Preparation of Purine Derivatives Having Phosphodiesterase IV Inhibiting Activity. World Patent Application WO 9931102A1, June 24, 1999.
79. Gale, D. D.; Hofer, P.; Spina, D.; Seeds, E. A.; Banner, K. H.; Harrison, S.; Douglas, G.; Matsumoto, T.; Page, C. P.; Wong, R. H.; Jordan, S.; Smith, F.; Banik, N.; Halushka, P. V.; Cavalla, D.; Rotshteyn, Y.; Kyle, D. J.; Burch, R. M.; Chasin, M. Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294. Pulm. Pharmacol. Ther. 2003, 16, 97-104.
80. Subrahmanyam, V.; Renwick, A. B.; Walters, D. G.; Price, R. J.; Tonelli, A. P.; Lake, B. G. Metabolism of a novel phosphodiesterase-IV inhibitor (V11294) by human hepatic cytochrome P450 forms. Xenobiotica 2002, 32, 521-534.
81. Whitehead, J. W. F.; Lee, G. P.; Gharagozloo, P.; Hofer, P.; Gehrig, A.; Wintergerst, P.; Smyth, D.; McCoull, W.; Hachicha, M.; Patel, A.; Kyle, D. J. 8-Substituted Analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl- adenine: highly potent and selective PDE4 inhibitors. J. Med. Chem. 2005, 48, 1237-1243.
82. (a) Palfreyman, M. N.; Souness, J. E. Phosphodiesterase Type IV Inhibitors. In Progress in Medicinal Chemistry; Ellis, G. P., Luscombe, D. K., Eds.; Elsevier Science: Amsterdam, 1996; Vol. 33, pp 1-52.
83. (b) Dent, G.; Giembycz, M. A. Selective phosphodiesterase inhibitors in the therapy of asthma. Clin. Immunother. 1995, 3, 423-437.
84. Muller, T.; Engels, P.; Fozard, J. R. Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol. Sci. 1996, 17, 294-298.
85. Duplantier, A. J.; Andresen, C. J.; Cheng, J. B.; Cohan, V. L.; Decker, C.; DiCapua, F. M.; Kraus, K. G.; Johnson, K. L.; Turner, C. R.; Umland, J. P.; Watson, J. W.; Wester, R. T.; Williams, A. S.; Williams, J. A. 7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo-[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase. J. Med. Chem. 1998, 41, 2268-2277.
86. Duplantier, A. J.; Bachert, E. L.; Cheng, J. B.; Cohan, V. L.; Jenkinson, T. H.; Kraus, K. G.; McKechney, M. W.; Pillar, J. D.; Watson, J. W. SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3- α]pyridines as potent inhibitors of human eosinophil phosphodiesterase. J. Med. Chem. 2007, 50, 344-349.
87. De Boer, J.; Philpott, A. J.; Van Amsterdam, R. G.; Shahid, M.; Zaagsma, J.; Nicholson, C. D. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br. J. Pharmacol. 1992, 106, 1028-1034.
88. Torphy, T. J.; Undem, B. J.; Cieslinski, L. B.; Luttmann, M. A.; Reeves, M. L.; Hay, D. W. P. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J. Pharmacol. Exp. Ther. 1993, 265, 1213-1223.
89. Van der Mey, M.; Hatzelmann, A.; Van der Laan, I. J.; Sterk, G. J.; Thibaut, U.; Timmerman, H. Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4- dimethoxyphenyl)-2H-phthalazin-1-ones and analogues. J. Med. Chem. 2001, 44, 2511-2522.
90. Van der Mey, M.; Boss, H.; Hatzelmann, A.; Van der Laan, I. J.; Sterk, G. J.; Timmerman, H. Novel selective PDE4 inhibitors. 3. In vivo anti-inflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones. J. Med. Chem. 2002, 45, 2520-2525.
91. Van der Mey, M.; Hatzelmann, A.; Van Klink, G. P. M.; Van der Laan, I. J.; Sterk, G. J.; Thibaut, U.; Ulrich, W. R.; Timmerman, H. Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones. J. Med. Chem. 2001, 44, 2523-2535.
92. Van der Mey, M.; Bommele, K. M.; Boss, H.; Hatzelmann, A.; Van Slingerland, M.; Sterk, G. J.; Timmerman, H. Synthesis and structure - activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents. J. Med. Chem. 2003, 46, 2008-2016.
93. Piza, V. D.; Giovannoni, M. P.; Castellana, C. Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors. J. Med. Chem. 1997, 40, 1417-1421.
94. (a) Wilhem, R.; Loe, B.; Alvarez, R.; Devens, B.; Fong, A. Pyrido-[2,3-d]pyridazinones as Potent and Selective Type 4 Phosphodiesterase Inhibitors. Presented at the 8th RSC-SCI Medicinal Chemistry Symposium, Cambridge, U.K., 1995, P32.
95. (b) Alvarez, R.; Daniels, D. V.; Shelton, E. R.; Baecker, P. S.; Fong, T. A. T.; Devens, B.; Wilhelm, R.; Eglen, R. M.; Cont, M. An Isoform-Selective Inhibitor of Cyclic AMP-Specific Phosphodiesterase (PDE 4) with Antiinflammatory Properties. In Phosphodiesterase Inhibitors; Schudt, C., Dent, G., Rabe, K. F., Eds.; Academic Press: London, 1996; pp 161-171.
96. Manabe, H.; Ohnuma, K.; Ichimura, M.; Kawakita, T.; Suzuki, F.; Ohmori, K. Pharmacological Properties of a New Bronchodilator, KF19514. Presented at the 68th Annual Meeting of the Japanese Pharmacological Society, Nagoya, Japan, 1995; S24-4.
97. Suzuki, F.; Kuroda, T.; Kawakita, T.; Manabe, H.; Kitamura, S.; Ohmori, K.; Ichimura, M.; Kase, H.; Ichikawa, S. New bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones. J. Med. Chem. 1992, 35, 4866-4874.
98. Suzuki, F.; Kuroda, T.; Tamura, T.; Sato, S.; Ohmori, K.; Ichikawa, S. New antiinflammatory agents. 2. 5-Phenyl-3H-imidazo[4,5-c][1,8] naphthyridin-4(5H)-ones: a new class of nonsteroidal antiinflammatory agents with potent activity like glucocorticoids. J. Med. Chem. 1992, 35, 2863-2870.
99. Irvine, M. W.; Patrick, G. L.; Kewney, J.; Hastings, S. F.; MacKenzie, S. J. Rhodanine derivatives as novel inhibitors of PDE4. Bioorg. Med. Chem. Lett. 2008, 18, 2032-2037.
100. (a) Hersperger, R.; Bray-French, K.; Mazzoni, L.; Muller, T. Palladium-catalyzed cross-coupling reactions for the synthesis of 6,8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors. J. Med. Chem. 2000, 43, 675-682.
101. (b) Hersperger, R.; Dawson, J.; Mueller, T. Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor. Bioorg. Med. Chem. Lett. 2002, 12, 233-235.
102. Huang, Z.; Dias, R.; Jones, T.; Liu, S.; Styhler, A.; Claveau, D.; Otu, F.; Ng, K.; Laliberté, F.; Zhang, L.; Goetghebeur, P.; Abraham, W. M.; Macdonald, D.; Dubé, D.; Gallant, M.; Lacombe, P.; Girard, Y.; Young, R. N.; Turner, M. J.; Nicholson, D. W.; Mancini, J. A. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition. Biochem. Pharmacol. 2007, 73, 1971-1981.
103. Macdonald, D.; Mastracchio, A.; Perrier, H.; Dubé, D.; Gallant, M.; Lacombe, P.; Deschênes, D.; Roy, B.; Scheigetz, J.; Bateman, K.; Li, C.; Trimble, L. A.; Day, S.; Chauret, N.; Nicoll-Griffith, D. A.; Silva, J. M.; Huang, Z.; Laliberté, F.; Liu, S.; Ethier, D.; Pon, D.; Muise, E.; Boulet, L.; Chan, C. C.; Styhler, A.; Charleson, S.; Mancini, J.; Masson, P.; Claveau, D.; Nicholson, D. W.; Turner, M. J.; Young, R. N.; Girard, Y. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. Bioorg. Med. Chem. Lett. 2005, 15, 5241-5246.
104. Gallant, M.; Chauret, N.; Claveau, D.; Day, S.; Deschenes, D.; Dubé, D.; Huang, Z.; Lacombe, P.; Laliberté, F.; Lévesque, J. F.; Liu, S.; Macdonald, D.; Mancini, J.; Masson, P.; Mastracchio, A.; Nicholson, D.; Nicoll-Griffith, D. A.; Perrier, H.; Salem, M.; Styhler, A.; Young, R. N.; Girard, Y. Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 1407-1412.
105. Lacombe, P.; Deschênes, D.; Dubé, D.; Dube', L.; Gallant, M.; Macdonald, D.; Mastracchio, A.; Perrier, H.; Charleson, S.; Huang, Z.; Laliberte, F.; Liu, S.; Mancini, J. A.; Masson, P.; Salem, M.; Styhler, A.; Girard, Y. Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 2608-2612.
106. Wilhelm, R. S.; Fatheree, P. R.; Chin R. L. Quinolines as Type IV Phosphodiesterase Inhibitors. World Patent Application WO 9422852, October 13, 1994.
107. Macdonald, D.; Perrier, H.; Liu, S.; Laliberté, F.; Rasori, R.; Robichaud, A.; Masson, P.; Huang, Z. Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl]quinoline (API-IMQ). J. Med. Chem. 2000, 43, 3820-3823.
108. Iwasaki, T.; Kondo, K.; Kuroda, T.; Moritani, Y.; Yamagata, S.; Sugiura, M.; Kikkawa, H.; Kaminuma, O.; Ikezawa, K. Novel selective PDE IV inhibitors as anti-asthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans. J. Med. Chem. 1996, 39, 2696-2704.
109. Ukita, T.; Sugahara, M.; Terakawa, Y.; Kuroda, T.; Wada, K.; Nakata, A.; Yasushi Ohmachi, Y.; Kikkawa, H.; Ikezawa, K.; Naito, K. Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridyl-naphthalene derivatives. J. Med. Chem. 1999, 42, 1088-1099.
110. Provins, L.; Christophe, B.; Danhaive, P.; Dulieu, J.; Durieu, V.; Gillard, M.; Lebon, F.; Lengelé, S.; Quéré, L.; Keulena, B. v. First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives. Bioorg. Med. Chem. Lett. 2006, 16, 1834-1839.
111. Pascal, Y.; Andrianjara, C. R.; Auclair, E.; Avenel, N.; Bertin, B.; Calvet, A.; Feru, F.; Lardon, S.; Moodley, I.; Ouagued, M.; Payne, A.; Pruniaux, M.-P.; Szilagyi, C. Synthesis and structure - activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 35-38.
112. Burnouf, C.; Auclair, E.; Avenel, N.; Bertin, B.; Bigot, C.; Calvet, A.; Chan, K.; Durand, C.; Fasquelle, V.; Feru, F.; Gilbertsen, R.; Jacobelli, H.; Kebsi, A.; Lallier, E.; Maignel, J.; Martin, B.; Milano, S.; Ouagued, M.; Pascal, Y.; Pruniaux, M.-P.; Puaud, J.; Rocher, M.-N.; Terrasse, C.; Wrigglesworth, R.; Doherty, A. M. Synthesis, structure - activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4] diazepino[6,7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors. J. Med. Chem. 2000, 43, 4850-4867.
113. Devillers, I.; Pevet, I.; Jacobelli, H.; Durand, C.; Fasquelle, V.; Puaud, J.; Gaudilliere, B.; Idrissi, M.; Moreau, F.; Wrigglesworth, R. New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 3303-3306.
114. (a) Ochiai, H.; Ishida, A.; Ohtani, T.; Kusumi, K.; Kishikawa, K.; Yamamoto, S.; Takeda, H.; Obata, T.; Nakaia, H.; Toda, M. New orally active PDE4 inhibitors with therapeutic potential. Bioorg. Med. Chem. 2004, 12, 4089-1100.
115. (b) Allen, D. G.; Coe, D. M.; Cook, C. M.; Dowle, M. D.; Edlin, C. D.; Hamblin, J. N.; Johnson, M. R.; Jones, P. S.; Lindvall, M. K.; Mitchell, C. J.; Redgrave, A. J.; Robinson, J. E.; Trivedi, N. Pyazolo[3,4-b]pyridine Compounds, and Their Use as PDE4 Inhibitors. U.S. Patent Application US 2008/0132536 A1, June 5, 2008.
116. Buckley, G. M.; Cooper, N.; Dyke, H. J.; Galleway, F.; Gowers, L.; Haughan, A. F.; Kendall, H. J.; Lowe, C.; Maxey, R.; Montana, J. G.; Naylor, R.; Oxford, J.; Peake, J. C.; Picken, C. L.; Runcie, K. A.; Sabin, V.; Sharpe, A.; Warneck, J. B. H. 8-Methoxyquinoline-5-carboxamides as PDE4 Inhibitors: a potential treatment for asthma. Bioorg. Med. Chem. Lett. 2002, 12, 1613-1615.
117. Billah, M.; Buckley, G. M.; Cooper, N.; Dyke, H. J.; Egan, R.; Ganguly, A.; Gowers, L.; Haughan, A. F.; Kendall, H. J.; Lowe, C.; Minnicozzi, M.; Montana, J. G.; Oxford, J.; Peake, J. C.; Picken, C. L.; Piwinski, J. J.; Naylor, R.; Sabin, V.; Shih, N.-Y.; Warneck, J. B. H. 8-Methoxyquinolines as PDE4 inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 1617-1619.
118. Billah, M.; Cooper, N.; Cuss, F.; Davenport, R. J.; Dyke, H. J.; Egan, R.; Ganguly, A.; Gowers, L.; Hannah, D. R.; Haughan, A. F.; Kendall, H. J.; Lowe, C.; Minnicozzi, M.; Montana, J. G.; Naylor, R.; Oxford, J.; Peake, J. C.; Piwinski, J. J.; Runcie, K. A.; Sabin, V.; Sharpe, A.; Shih, N.-Y.; Warneck, J. B. H. Synthesis and profile of SCH351591, a novel PDE4 inhibitor. Bioorg. Med. Chem. Lett. 2002, 12, 1621-1623.
119. Kuang, R.; Shue, H.-J.; Blythin, D. J.; Shih, N.-Y.; Gu, D.; Chen, X.; Schwerdt, J.; Lin, L.; Ting, P. C.; Zhu, X.; Aslanian, R.; Piwinski, J. J.; Xiao, L.; Prelusky, D.; Wu, P.; Zhang, J.; Zhang, X.; Celly, C. S.; Minnicozzi, M.; Billahd, M.; Wangd, P. Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 5150-5154.
120. Napoletano, M.; Norcini, G.; Pellacini, F.; Marchini, F.; Morazzoni, G.; Ferlengab, P.; Pradellab, L. The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I. Bioorg. Med. Chem. Lett. 2000, 10, 2235-2238.
121. Napoletano, M.; Norcini, G.; Pellacini, F.; Marchini, F.; Morazzoni, G.; Ferlenga, P.; Pradella, L. Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives. Bioorg. Med. Chem. Lett. 2001, 11, 33-37.
122. Napoletano, M.; Norcini, G.; Pellacini, F.; Marchini, F.; Morazzoni, G.; Fattori, R.; Ferlenga, P.; Pradella, L. Phthalazine PDE4 inhibitors. Part 3: The synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor. Bioorg. Med. Chem. Lett. 2002, 12, 5-8.
123. Raboisson, P.; Schultz, D.; Muller, C.; Reimund, J.-M.; Pinna, G.; Mathieu, R.; Bernard, P.; Do, Q.-T.; DesJarlais, R. L.; Justiano, H.; Lugnier, C.; Bourguignon, J.-J. Cyclic nucleotide phosphodiesterase type 4 inhibitors: evaluation of pyrazolo[1,5-a]-1,3,5-triazine ring system as an adenine bioisostere. Eur. J. Med. Chem. 2008, 43, 816-829.
124. Huang, Z.; Liu, S.; Zhang, L.; Salem, M.; Greig, G. M.; Chan, C. C.; Natsumeda, Y.; Noguchi, K. Preferential inhibition of human phosphodiesterase 4 by ibudilast. Life Sci. 2006, 78, 2663-2668.
125. Fitzgerald, M. F.; Fox, J. C. Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development. Drug Discovery Today 2007, 12, 479-186.
126. Kuss, H.; Hoefgen, N.; Johanssen, S.; Kronbach, T.; Rundfeldt, C. In vivo